Wealth Quarterback LLC Has $2.81 Million Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Wealth Quarterback LLC reduced its position in Johnson & Johnson (NYSE:JNJ) by 14.1% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 17,325 shares of the company’s stock after selling 2,847 shares during the period. Johnson & Johnson comprises 1.5% of Wealth Quarterback LLC’s holdings, making the stock its 15th largest position. Wealth Quarterback LLC’s holdings in Johnson & Johnson were worth $2,808,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of JNJ. China Universal Asset Management Co. Ltd. acquired a new stake in Johnson & Johnson during the first quarter worth approximately $765,000. Noesis Capital Mangement Corp boosted its stake in Johnson & Johnson by 21.3% in the 1st quarter. Noesis Capital Mangement Corp now owns 8,031 shares of the company’s stock valued at $1,270,000 after purchasing an additional 1,410 shares during the period. Keener Financial Planning LLC grew its holdings in Johnson & Johnson by 42.1% in the 1st quarter. Keener Financial Planning LLC now owns 361 shares of the company’s stock valued at $58,000 after buying an additional 107 shares in the last quarter. SPC Financial Inc. lifted its holdings in shares of Johnson & Johnson by 2.7% during the first quarter. SPC Financial Inc. now owns 17,008 shares of the company’s stock worth $2,690,000 after buying an additional 441 shares in the last quarter. Finally, Hemenway Trust Co LLC grew its stake in shares of Johnson & Johnson by 1.2% in the first quarter. Hemenway Trust Co LLC now owns 212,169 shares of the company’s stock valued at $33,563,000 after acquiring an additional 2,435 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Transactions at Johnson & Johnson

In related news, VP Robert J. Decker sold 5,635 shares of the firm’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. TD Cowen cut their price objective on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, July 18th. TD Securities reduced their price target on Johnson & Johnson from $195.00 to $185.00 in a research report on Thursday, July 18th. Guggenheim upped their target price on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a research report on Wednesday. Royal Bank of Canada raised their price target on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 16th. Finally, StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, September 14th. Seven research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $175.00.

Johnson & Johnson Stock Down 0.8 %

Shares of NYSE:JNJ opened at $155.47 on Friday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $168.85. The company has a market capitalization of $374.31 billion, a PE ratio of 22.50, a price-to-earnings-growth ratio of 2.80 and a beta of 0.53. The company has a fifty day moving average of $162.61 and a 200-day moving average of $155.81.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same period last year, the company earned $2.66 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. On average, equities analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.19%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.